Selling Congress On DTC User Fees: AstraZeneca Uses Guilt
Executive Summary
AstraZeneca U.S. CEO Tony Zook wants Congress to understand the company's "disappointment" in the failure of FDA's user fee program for direct-to-consumer advertising to get off the ground. The system is "good for patients, good public policy, and a sensible way to help alleviate concerns that have been expressed about the tone and content of some DTC," Zook says in an April 24 letter to the leadership of the Senate Health and House Commerce Committees.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth